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sevier Taiwan LLC.Open access under CSummary Background: Esophageal candidiasis (EC) often occurs in human immunodeficiency
virus (HIV)-infected patients, but is uncommon in non-HIV-infected patients. It is known that
malignancy, diabetes mellitus, previous gastric surgery, and medications (antibiotics, proton
pump inhibitors, and steroids) are risk factors for esophageal candidiasis in non-HIV-infected
patients. However, the relationship between liver cirrhosis and esophageal candidiasis was un-
clear. This study aimed to elucidate the role of liver cirrhosis in esophageal candidiasis.
Methods: A retrospective chart review study was conducted on non-HIV-infected patients with
esophageal candidiasis who presented to Tri-Service General Hospital from January 2009 to
December 2012. The diagnosis of EC was primarily based on endoscopic findings. The incidence
of EC in cirrhotic and noncirrhotic patients was compared. Furthermore, differences in base-
line characteristics, clinical variables, and mortality after antifungal treatment between the
two groups were analyzed.
Results: In this study, 43,217 non-HIV-infected patients were enrolled, 3017 of whom had liver
cirrhosis. The incidence of EC in cirrhotic patients was higher than that in noncirrhotic patients
(0.8% vs. 0.36%; relative risk Z 2.2; p < 0.001). Multivariate logistic regression analysis iden-
tified liver cirrhosis as an independent risk factor for EC (odds ratio, 1.74; 95% confidence in-
terval, 1.06e2.87; p Z 0.029). Moreover, cirrhotic patients tended to be asymptomatic
compared with noncirrhotic patients (45.8% vs. 9%; p < 0.01). The most common coexisting
endoscopic finding was reflux esophagitis (83.9%). However, antifungal treatment did not
decrease the mortality of patients with EC during hospitalization.Gastroenterology, Tri-Service General Hospital, Number 325, Section 2, Cheng-Gong Road, Neihu,
o.com.tw (H.-H. Lin).
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cirrhotic patients. Although antifungal treatment did not improve the outcome in this study,
a prospective study is still required to investigate this issue.
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Esophageal candidiasis (EC) is a common opportunistic
infection that occurs most often in immunocompromised
patients who have either AIDS caused by human immuno-
deficiency virus (HIV) infection, or iatrogenic immunosup-
pression caused by cancer treatment and prevention of
transplanted-organ rejection [1e6]. In non-HIV-infected
patients, the prevalence of EC is approximately 0.3%
[7e9]. However, prior to the introduction of highly active
antiretroviral therapy, 42% of HIV-infected patients had
been diagnosed with EC [10]. Under current highly active
antiretroviral therapy regimens, 17% of HIV-infected pa-
tients experience EC [10], suggesting that the incidence of
EC has substantially increased in HIV-infected patients.
Similarly, renal allograft recipients who received three
immunosuppressive drugs had a higher incidence of EC
compared with recipients who took two immunosuppres-
sive drugs (28.6% vs. 10.4%) [6]. These examples demon-
strate that the incidence of EC is related to immune
status.
Candida albicans is the most common pathogen causing
EC. It has been isolated from 90% of EC patients [11,12].
The common presenting symptoms are odynophagia,
dysphagia, and retrosternal pain [2], but some patients are
asymptomatic [13e16]. Esophagogastroduodenoscopy
(EGD) plays an important role in the diagnosis of EC. EGD
reveals the gross appearance of esophageal mucosa and
provides an opportunity to perform biopsy [1,16e18]. The
typical endoscopic appearance is multiple raised small or
thick white plaques on the esophageal mucosa [1,10,16].
Histological examination of the biopsy specimens using a
potassium hydroxide smear reveals yeast cells and pseu-
dohyphae [19,20]. Sensitivity and specificity of EGD for the
diagnosis of EC are 100% and 83.3%, respectively; positive
and negative predictive values are 88.5% and 100%,
respectively [17]. Therefore, EGD is a reliable method for
the diagnosis of EC.
Among HIV-negative patients, those with cancer have a
higher incidence of EC compared with those without
cancer [4,7,8,21]. A double-blind study showed that
oropharyngeal candidiasis was detected in 54% of cancer
patients who received placebo and in 3% of cancer pa-
tients who received antifungal prophylaxis during hospi-
talization [22]. Another double-blind study also revealed
that 78.6% of patients with acute leukemia undergoing
chemotherapy developed oropharyngeal candidiasis, but
only 7.1% of acute leukemia patients undergoing both
chemotherapy and antifungal prophylaxis had oropharyn-
geal candidiasis [5]. Furthermore, oropharyngeal candi-
diasis is a marker for EC in cancer patients [4], suggestingthat the risk for EC is increased in cancer patients. Simi-
larly, other risk factors have been proven to increase the
incidence of EC, such as diabetes mellitus (DM), previous
gastric surgery, reflux esophagitis, and use of antibiotics,
steroids, and proton pump inhibitors (PPIs)
[6e9,16,23e25]. In addition, the number of CD4þ T cells is
crucial for determining the immune status, and it was
decreased in cirrhotic patients [26]. The decrease in CD4þ
T-cell count plays an important role in the disease pro-
gression of HIV-infected patients [27,28]. Therefore, liver
cirrhosis, similar to HIV infection, may also increase the
incidence of EC. However, the relationship between
cirrhosis and EC remains unclear.
In this study, our aim was to elucidate the role of liver
cirrhosis in non-HIV-infected patients with EC. The clinical
characteristics and symptoms of our patients with EC were
first examined, and subsequently coexisting endoscopic
findings were investigated. Finally, we analyzed the puta-
tive predisposing factors, and determined whether liver
cirrhosis was an independent risk factor for EC.
Materials and methods
Patients
In this retrospective study, medical records of patients who
underwent EGD at Tri-Service General Hospital, Taipei,
Taiwan from January 2009 to December 2012 were
analyzed. Age, sex, symptoms, medical history (such as
liver cirrhosis, DM, malignancy, or end-stage renal disease),
medications (such as PPIs, antibiotics, corticosteroids,
immunosuppressive drugs, or chemotherapy), and endo-
scopic findings were investigated. HIV-infected patients
were excluded from the study. The diagnosis of EC was
based on the findings of endoscopy (Fig. 1) or biopsy. To
verify the diagnosis of EC, endoscopic images were
reviewed by two endoscopists.
Patients with EC were divided into two groups. The first
group (Group 1) was associated with liver cirrhosis and the
second group (Group 2) was without cirrhosis. The diagnosis
of cirrhosis was based on the findings of coarsening paren-
chymal echo pattern, irregular surface, enlargement of
caudate lobe, vascular irregularities, accompanied with
splenomegaly, or ascites in abdominal sonography. The
incidence rate of EC in the two groups was calculated. To
confirm whether liver cirrhosis is an independent risk factor
of EC, different putative risk factors were compared be-
tween these two groups. The mortality after antifungal
treatment between the two groups was also analyzed. The
study was approved by the Institutional Review Board of
Tri-Service General Hospital.
Figure 1 Endoscopic images of esophageal candidiasis
showed that whitish plaques were scattered over esophageal
mucosa.
88 T.-M. Ou et al.Statistical analysis
All data are presented as the mean  standard deviation for
continuous variables, or the number (percentage) for cat-
egorical variables. Statistical analysis was performed using
PASW (Predictive Analytics SoftWare) statistics software,
version 18 (IBM Co., Somers, NY, USA). Continuous variables
were compared using Student t test, and categorical vari-
ables were compared using Chi-square or Fisher exact tests.
A logistic regression mode was used to control known risk
factors and analyze the association of liver cirrhosis and EC.
All reported p-values were two-tailed, and p < 0.05 was
considered significant.
Results
The incidence of EC increased in cirrhotic patients
During 2009e2012, 43,217 patients underwent EGD at our
hospital and 168 patients were diagnosed with EC (156 by
endoscopic finding and 12 by biopsy). The incidence rate of
EC over all cases of EGD was 0.39%. The characteristics and
clinical symptoms of 168 patients are shown in Table 1.
Group 1 (with liver cirrhosis) comprised 24 patients and
Group 2 (without liver cirrhosis) comprised 144 cases.
Although the mean age was older in Group 1 (63.38  10.7
years) than in Group 2 (62.99  14.87 years), the difference
did not reach statistical significance. The males were pre-
dominant in both groups, and there was no difference in the
sex proportion between these two groups. Among the pa-
tients, 3017 had liver cirrhosis. Therefore, the incidence
rate of EC in cirrhotic patients was 0.8% and in noncirrhotic
patients was 0.36%, suggesting that the risk of EC was
increased in cirrhotic patients compared with noncirrhotic
patients (relative risk Z 2.2, p < 0.001). In cirrhotic pa-
tients, 1398 were ChildePugh A and eight had EC (0.57%);
1087 were ChildePugh B and seven had EC (0.64%); 532were ChildePugh C and nine had EC (1.69%). The incidence
of EC was higher in cirrhotic patients with ChildePugh C
compared with the others (p Z 0.037).
Cirrhotic patients with EC may be asymptomatic
None of the cases in either group underwent EGD due to
suspected EC. Most of them underwent EGD due to sus-
pected reflux esophagitis or peptic ulcer disease, suspected
upper gastrointestinal tract bleeding, follow-up of reflux
esophagitis or peptic ulcer disease, suspected esophageal
varices, or anemia with unknown cause. The common
clinical symptoms among all cases of EC were epigastric
pain (48.2%), acid regurgitation (23.8%), and hematemesis/
melena (14.9%). However, there were fewer patients with
epigastric pain or acid regurgitation in Group 1 than in
Group 2 (p < 0.05). Apart from epigastric pain and acid
regurgitation, there were no statistically significant dif-
ferences in the other presenting symptoms. By contrast,
almost half of the cases in Group 1 were asymptomatic,
which was significantly more than in Group 2 (45.8% vs. 9%,
p < 0.01), suggesting that cirrhotic patients may not pre-
sent specific gastrointestinal symptoms when they contract
EC.
Endoscopic findings coexisting with EC
The endoscopic findings coexisting with EC among all cases
of EC were reflux esophagitis (83.9%), gastritis (65.5%),
duodenitis (35.7), gastric ulcer (24.4%), duodenal ulcer
(13.1%), esophageal varices (7.1%), gastric cancer (1.8%),
and esophageal cancer (0.6%; Table 2). No differences were
observed in the endoscopic findings between Groups 1 and
2, except that esophageal varices were prominent in Group
1 (p < 0.001). The most common location of EC was the
lower third of the esophagus (43.5%). Similarly, there was
no difference in the distribution of EC between these two
groups.
Liver cirrhosis is an independent risk factor for EC
Underlying disorders (such as HIV infection, malignancy,
and DM), previous gastric surgery and medications (such as
antibiotics, steroids, and PPIs) are known risk factors for EC
[6e8,16,23]. The presentation of these risk factors was
analyzed in patients with EC (Table 3). In this study, HIV-
positive patients were excluded. Malignancy, DM, previous
gastric surgery, and medications (antibiotics, steroids, and
PPIs) were related to EC. To test whether liver cirrhosis is
an independent risk factor for EC, a multivariate logistic
regression was used to analyze these risk factors (Table 4),
and it revealed that liver cirrhosis was significantly associ-
ated with EC [odds ratio (OR), 1.74; 95% confidence interval
(CI), 1.06e2.87; p Z 0.029]. However, the association of
DM (OR, 0.78; 95% CI, 0.52e1.19; pZ 0.255) and antibiotics
(OR, 0.91; 95% CI, 0.57e1.42; p Z 0.664) with EC did not
reach statistical significance. These results suggest that
liver cirrhosis is an independent risk factor for EC, similar to
malignancy, previous gastric surgery, and medications
(steroids and PPIs).
Table 1 Clinical characteristics of patients with esophageal candidiasis.
Group 1 (with cirrhosis) Group 2 (without cirrhosis)
Number 24 144
Age (y) Mean  SD 63.38  10.7 62.99  14.87
Range 48e93 19e90
Sex (male/female) 17/7 86/58
Symptoms (%) Asymptomatic** 11 (45.8) 13 (9)
Acid regurgitation* 1 (4.2) 39 (27.1)
Dysphagia 1 (4.2) 6 (4.2)
Odynophagia 0 (0) 5 (3.5)
Retrosternal pain 0 (0) 7 (4.9)
Epigastric pain** 5 (20.8) 76 (52.8)
Hematemesis/melena 5 (20.8) 20 (13.9)
Nausea/vomiting 2 (8.3) 6 (4.2)
Dyspepsia 0 (0) 5 (3.5)
Other GI symptoms 1 (4.2) 4 (2.8)
*p < 0.05.
**p < 0.01.
GI Z gastrointestinal; SD Z standard deviation.
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of EC
Eighty-two patients with EC underwent antifungal treat-
ment, and 93.9% of these patients were alive when they
were discharged from the hospital. By contrast, 86 patients
with EC did not receive any antifungal drugs, and 91.9% of
patients were alive when they were discharged from the
hospital. There was no difference in the mortality during
hospitalization between patients with and without anti-
fungal treatment. Within Group 1, 15 patients had been
treated with anti-fungal drugs and 12 were alive when they
were discharged form hospital (2 died of hepatocellular
carcinoma, and 1 died of disseminated candidiasis with
septic shock); nine patients did not receive any antifungalTable 2 Endoscopic findings of patients with esophageal
candidiasis.
Findings (%) Group 1 Group 2
Negative except
esophageal candidiasis
1 (4.2) 3 (2.1)
Reflux esophagitis 18 (75) 123 (85.4)
Esophageal cancer 0 (0) 1 (0.7)
Esophageal varices 12 (50) 0 (0)
Gastric ulcer 9 (37.5) 32 (22.2)
Gastric cancer 0 (0) 3 (2.1)
Gastritis 16 (66.7) 94 (65.3)
Duodenal ulcer 1 (4.2) 21 (14.6)
Duodenitis 13 (54.2) 47 (32.6)
Location
Whole 4 (16.7) 21 (14.6)
U/3 0 (0) 3 (2.1)
U/3eM/3 5 (20.8) 14 (9.7)
M/3 0 (0) 16 (11.1)
M/3eL/3 4 (16.7) 28 (19.4)
L/3 11 (45.8) 62 (43.1)
L/3 Z lower third; M/3 Z middle third; U/3 Z upper third.drugs and six were alive when they were discharged form
hospital (3 died of decompensated cirrhosis). Antifungal
treatment did not decrease the mortality in cirrhotic pa-
tients with EC (20% vs. 33.3%, pZ 0.46). Within Group 2, 67
patients had been treated with antifungal drugs and 65
were alive when they were discharged from the hospital (1
died of hepatocellular carcinoma, and 1 died of colon
cancer); 77 patients did not receive antifungal drugs and 73
were alive when they were discharged from the hospital (2
died of gastric cancer, 1 died of hepatocellular carcinoma,
and 1 died of lung cancer). Antifungal treatment did not
decrease the mortality in the noncirrhotic patients with EC
(3% vs. 5.2%, p Z 0.51).
Discussion
EC is an unusual problem in the general population. In this
study, the incidence of EC in HIV-negative patients wasTable 3 Risk factors for acquisition of esophageal
candidiasis.
Risk factors No. (%) of
patients with
esophageal
candidiasis
No. (%) of
patients without
esophageal
candidiasis
p
Malignancy 39 (23.2)* 5430 (12.6) < 0.001
DM 40 (23.8) 7536 (17.5) 0.041
Antibiotics 27 (16.1) 4729 (11.0) 0.048
Steroids 10 (6.0) 1169 (2.7) 0.019
PPIs 25 (14.9) 3549 (8.2) 0.003
Gastric surgery 8 (4.8) 842 (2.0) 0.019
Liver cirrhosis 24 (14.3) 2993 (7.0) < 0.001
DM Z diabetes mellitus; PPIs Z proton pump inhibitors.
* Hepatocellular carcinoma (n Z 14), lung cancer (n Z 5),
colon cancer (n Z 5), nasopharyngeal cancer (n Z 4), gastric
cancer (nZ 3), bladder cancer (nZ 3), breast cancer (nZ 1),
cholangiocarcinoma (n Z 1), esophageal cancer (n Z 1), lym-
phoma (n Z 1), thyroid cancer (n Z 1).
Table 4 Results of multivariate logistic regression analysis
of risk factors associated with esophageal candidiasis.
Risk factors Odds ratio (95% CI) p
Malignancy 8.43 (5.74e12.39) < 0.001
DM 0.78 (0.52e1.19) 0.255
Antibiotics 0.91 (0.57e1.42) 0.664
Steroids 2.26 (1.1e4.68) 0.027
PPIs 8.86 (5.61e13.97) < 0.001
Gastric surgery 6.81 (3.36e13.79) < 0.001
Liver cirrhosis 1.74 (1.06e2.87) 0.029
CI Z confidence interval; DM Z diabetes mellitus;
PPIs Z proton pump inhibitors.
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previous reports [7e9].
Candida colonization of the mucosal surface is common
in the esophagus [29]. Once the host’s immunity is
impaired, the colonizing candida may have the opportunity
to invade the epithelium and develop EC [30]. It had been
shown that the immune status of HIV-infected patients is
associated with the CD4þ T-cell count and that a decrease
in CD4þ T-cell count increases the incidence of opportu-
nistic infections [31e33]. EC is one of the opportunistic
infections that frequently develop in HIV-infected patients
[1e3]. In addition, the CD4þ T-cell count depletion is found
in cirrhotic patients and correlates with the severity of the
disease [26,34]. Therefore, the incidence of EC should be
increased in cirrhotic patients, similar to HIV-infected pa-
tients. In this study, the incidence of EC in cirrhotic pa-
tients was twice as high as noncirrhotic patients. This result
suggests that our hypothesis is correct.
Dysphagia, odynophagia, and retrosternal pain are
common presenting symptoms of EC, but some patients
with EC can be asymptomatic [2]. For example, 43% HIV-
infected patients with EC were asymptomatic [14].
Another study showed that 21.4% of patients who took
immunosuppressive drugs after renal transplantation were
asymptomatic when they had been diagnosed with EC [6].
By contrast, only 5.9% of HIV-negative patients with EC did
not present specific gastrointestinal symptoms [8], sug-
gesting that immunocompromised patients may tend to
present without symptoms. In our study, there was no sig-
nificant difference in the baseline characteristics and
coexisting endoscopic findings between cirrhotic and non-
cirrhotic patients with EC. However, 45.8% and 9% of EC
were asymptomatic in cirrhotic and noncirrhotic patients,
respectively. Only 4.2% of cirrhotic patients presented with
dysphagia and none presented with odynophagia or retro-
sternal pain. Therefore, similar to immunocompromised
patients, cirrhotic patients may tend to present with
asymptomatic EC.
Previous studies have shown that HIV infection, cancer,
DM, gastric surgery, and medications (antibiotics, steroids,
and PPIs) are risk factors for EC [6e8,16,23]. We analyzed
these putative risk factors and found that there was an
increased presentation of these known factors in patients
with EC. A multivariate logistic regression revealed that
liver cirrhosis is an independent risk factor for EC. However,
the associations of DM and antibiotics with EC were notsignificant after adjustment with other risk factors. It was
possible that DM and use of antibiotics were strongly
correlated with other risk factors, so it did not show sta-
tistical significance after adjustment.
In this study, the mortality was lower in patients
administered antifungal treatment than those without
antifungal treatment, but the difference did not reach
statistical significance, suggesting that antifungal treat-
ment did not affect the outcome of EC. However, this was a
retrospective study and the number of patients with EC was
not large enough to draw a strong conclusion. Therefore, a
double-blind randomized controlled study is needed to
resolve this issue.
In conclusion, liver cirrhosis is an independent risk factor
for EC. Furthermore, clinical manifestation of EC may be
asymptomatic or nonspecific in cirrhotic patients. Although
we have demonstrated in cirrhotic patients that the anti-
fungal treatment did not improve the outcome of EC, this
issue needs to be addressed by further study.Conflicts of interest
All authors declare no conflicts of interest.References
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